On March 14, 2023 Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage oncology company developing first-in-class1 therapeutics that combine both targeted and immune-mediated mechanisms, reported that two abstracts have been accepted for poster presentation at the 2023 American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting taking place April 14-19, 2023 in Orlando, FL (Press release, Tempest Therapeutics, MAR 14, 2023, View Source [SID1234628664]). The presentations will highlight biomarker data from the Phase 1 trial of TPST-1120, an oral selective PPAR⍺ antagonist and preclinical data from TREX1 inhibitor, a tumor-selective STING pathway activator.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Poster presentation details:
Title: Lipid and immune-based biomarkers associated with clinical response to TPST-1120: A small molecule antagonist of peroxisome-proliferator activated receptor-alpha
Session Category: Clinical Research Excluding Trials
Session Title: Biomarkers of Therapeutic Benefit 2
Session Date & Time: Monday, April 17, 2023 9:00 a.m. – 12:30 p.m. ET
Location: Poster Section 39
Abstract Number: 2130
Title: Generation of novel potent human TREX1 inhibitors facilitated by crystallography
Session Category: Experimental and Molecular Therapeutics
Session Title: Novel Antitumor Agents 3
Session Date & Time: Monday, April 17, 2023 9:00 a.m. – 12:30 p.m. ET
Location: Poster Section 17
Abstract Number: 1636
___________________________
1 If approved by the FDA
Abstracts are available for viewing via the AACR (Free AACR Whitepaper) Online Itinerary Planner located here, View Source!/10828.